Merck Nears $6B All-Cash Deal for Terns Pharma

Key Points of the Potential Acquisition

Pharmaceutical giant Merck is reportedly nearing a deal to acquire biotech firm Terns Pharma for approximately $6 billion in an all-cash transaction. The negotiations are said to be in advanced stages, with a potential agreement expected within days, according to a Financial Times report.

Strategic Move in Oncology

The potential acquisition is a significant step in Merck's strategy to reshape its oncology division. The company is actively building its portfolio around its blockbuster cancer drug, Keytruda, in preparation for the drug’s patent expiration in 2028. Acquiring Terns Pharma would bring new developmental assets into its pipeline.

Market Reaction and Impact

Following the news, shares of Terns Pharma, which focuses on developing treatments for chronic myeloid leukemia, surged by approximately 10% in after-hours trading. The deal highlights a trend of large pharmaceutical companies acquiring smaller biotech firms to secure future growth and innovation.

Summary and Outlook

If finalized, this acquisition would represent one of the larger biotech deals of the year. Investors and the broader market will closely monitor for an official announcement and details on how Terns' assets will be integrated into Merck's long-term strategy.

FAQ

Q: How much is the reported deal between Merck and Terns Pharma worth?
A: The deal is reportedly valued at approximately $6 billion in an all-cash transaction.

Q: Why is this acquisition important for Merck?
A: It is a strategic move to strengthen Merck's oncology pipeline ahead of its key drug, Keytruda, losing patent protection in 2028.

Source: Financial Times via Reuters